Treprostinil Turns Heads in Promising IPF Study
Inhaled treprostinil has shown promising results in preserving lung function in adults with idiopathic pulmonary fibrosis (IPF). The phase 3 TETON-1 study demonstrated significant improvements in forced vital capacity compared to placebo. Despite some adverse events leading to discontinuation, the findings suggest potential for inhaled therapies in treating IPF.
- ▪The TETON-1 study involved 598 adults with IPF, randomized to receive inhaled treprostinil or placebo over 52 weeks.
- ▪Treprostinil significantly improved forced vital capacity by 130.1 mL compared to placebo (P < .0001).
- ▪Cough was the most common adverse event, reported by 54.8% of the treprostinil group.
Opening excerpt (first ~120 words) tap to expand
Use of inhaled treprostinil significantly preserved lung function in adults with idiopathic pulmonary fibrosis (IPF), based on new data presented at American Thoracic Society (ATS) 2026 International Conference and simultaneously published in The New England Journal of Medicine.“There is a paucity of drugs available to treat IPF, and the agents that are approved have issues with tolerability and efficacy,” said lead author Steven D. Nathan, MD, a pulmonologist and Schar Chair in the Advanced Lung Disease and Lung Transplant Program at Inova Fairfax Hospital, Falls Church, Virginia.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
